JP2006506097A - インターフェロン−αのポリペプチドおよび結合体 - Google Patents

インターフェロン−αのポリペプチドおよび結合体 Download PDF

Info

Publication number
JP2006506097A
JP2006506097A JP2004570419A JP2004570419A JP2006506097A JP 2006506097 A JP2006506097 A JP 2006506097A JP 2004570419 A JP2004570419 A JP 2004570419A JP 2004570419 A JP2004570419 A JP 2004570419A JP 2006506097 A JP2006506097 A JP 2006506097A
Authority
JP
Japan
Prior art keywords
polypeptide
seq
amino acid
sequence
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004570419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506097A5 (enExample
Inventor
フィリップ エー． パッテン，
スリダー ゴヴィンダラジャン，
スリダー ビスワナサン，
トルベン ラウエスゴール ニッセン，
Original Assignee
マキシジェン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マキシジェン， インコーポレイテッド filed Critical マキシジェン， インコーポレイテッド
Publication of JP2006506097A publication Critical patent/JP2006506097A/ja
Publication of JP2006506097A5 publication Critical patent/JP2006506097A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004570419A 2002-11-18 2003-11-17 インターフェロン−αのポリペプチドおよび結合体 Pending JP2006506097A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42761202P 2002-11-18 2002-11-18
US50256003P 2003-09-12 2003-09-12
PCT/US2003/036682 WO2004046365A2 (en) 2002-11-18 2003-11-17 Interferon-alpha polypeptides and conjugates

Publications (2)

Publication Number Publication Date
JP2006506097A true JP2006506097A (ja) 2006-02-23
JP2006506097A5 JP2006506097A5 (enExample) 2007-01-11

Family

ID=32329174

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004570419A Pending JP2006506097A (ja) 2002-11-18 2003-11-17 インターフェロン−αのポリペプチドおよび結合体

Country Status (13)

Country Link
US (1) US20040219131A1 (enExample)
EP (1) EP1565205A4 (enExample)
JP (1) JP2006506097A (enExample)
KR (1) KR20050086498A (enExample)
AU (1) AU2003297285A1 (enExample)
BR (1) BR0316324A (enExample)
CA (1) CA2504267A1 (enExample)
IL (1) IL168049A0 (enExample)
MX (1) MXPA05005263A (enExample)
NO (1) NO20052363L (enExample)
NZ (1) NZ540043A (enExample)
RU (1) RU2005118998A (enExample)
WO (1) WO2004046365A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504909A (ja) * 2006-09-14 2010-02-18 メドジェニクス・メディカル・イスラエル・リミテッド 長期持続性の医薬製剤
JP2010513333A (ja) * 2006-12-21 2010-04-30 北京三元基因工程有限公司 インターフェロンα変異体およびそのポリエチレングリコール誘導体

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE439437T1 (de) 1999-01-05 2009-08-15 Univ Boston Verbessertes klonierungsverfahren
US7435562B2 (en) 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
US7959910B2 (en) 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
ATE466085T1 (de) * 2002-09-09 2010-05-15 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
JP2006519170A (ja) 2002-12-26 2006-08-24 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド サイトカイン、ケモカイン、増殖因子、ポリペプチドホルモン、およびレセプター結合活性が保存されたそのアンタゴニストのポリマー結合体
MXPA05006944A (es) 2002-12-26 2005-12-14 Mountain View Pharmaceuticals Conjugados polimericos de interferon-beta cion potencia biologica aumentada.
CA2516552A1 (en) * 2003-02-26 2004-09-10 Intermune, Inc. Polyethylene glycol modified interferon compositions and methods of use thereof
ES2720078T3 (es) * 2004-01-21 2019-07-17 Nektar Therapeutics Método para preparar polímeros terminados en ácido propiónico
AU2005245918A1 (en) * 2004-05-19 2005-12-01 F. Hoffmann-La Roche Ag Interferon-alpha polypeptides and conjugates
AU2005260664A1 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
JP2008519602A (ja) 2004-11-11 2008-06-12 モジュラー ジェネティクス， インコーポレイテッド 多様性を生じるためのラダーアセンブリおよびシステム
US9931413B2 (en) * 2005-04-06 2018-04-03 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
EP2399932B1 (en) * 2005-05-12 2016-11-16 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
AU2006299901A1 (en) * 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
US11535673B2 (en) * 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
CN103260649A (zh) 2010-06-15 2013-08-21 迈德詹尼克斯医疗以色列有限公司 长效药物制剂
US20130225789A1 (en) * 2012-02-29 2013-08-29 Yi Sun Polyethylene Glycol Having Hetero Multiple Functional Groups
AU2022328512A1 (en) * 2021-08-18 2024-03-28 Remd Biotherapeutics, Inc. Novel interferon variants and bifunctional fusion molecules thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069913A1 (en) * 1999-05-19 2000-11-23 Lexigen Pharmaceuticals Corp. EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS
WO2001025438A2 (en) * 1999-10-07 2001-04-12 Maxygen, Inc. Ifn-alpha homologues
JP2001506855A (ja) * 1996-12-18 2001-05-29 マキシジェン，インコーポレイテッド ポリペプチド操作のための方法および組成物
WO2001095929A2 (en) * 2000-06-16 2001-12-20 Schering Aktiengesellschaft Interferon for treatment of multiple sclerosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4801685A (en) * 1981-08-14 1989-01-31 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L
US4678751A (en) * 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
IE54592B1 (en) * 1982-03-08 1989-12-06 Genentech Inc Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
EP0205404B1 (en) * 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
WO2002044197A2 (en) * 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
DE60307881T2 (de) * 2002-11-15 2007-03-08 F. Hoffmann-La Roche Ag Positionelle isomeren von pegyliertem interferon alpha 2a

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001506855A (ja) * 1996-12-18 2001-05-29 マキシジェン，インコーポレイテッド ポリペプチド操作のための方法および組成物
WO2000069913A1 (en) * 1999-05-19 2000-11-23 Lexigen Pharmaceuticals Corp. EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS
WO2001025438A2 (en) * 1999-10-07 2001-04-12 Maxygen, Inc. Ifn-alpha homologues
WO2001095929A2 (en) * 2000-06-16 2001-12-20 Schering Aktiengesellschaft Interferon for treatment of multiple sclerosis

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504909A (ja) * 2006-09-14 2010-02-18 メドジェニクス・メディカル・イスラエル・リミテッド 長期持続性の医薬製剤
JP2010513333A (ja) * 2006-12-21 2010-04-30 北京三元基因工程有限公司 インターフェロンα変異体およびそのポリエチレングリコール誘導体

Also Published As

Publication number Publication date
US20040219131A1 (en) 2004-11-04
EP1565205A2 (en) 2005-08-24
EP1565205A4 (en) 2006-07-05
CA2504267A1 (en) 2004-06-03
WO2004046365A3 (en) 2004-09-02
NO20052363D0 (no) 2005-05-12
IL168049A0 (en) 2009-02-11
MXPA05005263A (es) 2005-07-25
WO2004046365A2 (en) 2004-06-03
RU2005118998A (ru) 2006-01-27
KR20050086498A (ko) 2005-08-30
AU2003297285A1 (en) 2004-06-15
BR0316324A (pt) 2005-09-27
NO20052363L (no) 2005-08-08
NZ540043A (en) 2007-11-30

Similar Documents

Publication Publication Date Title
US7314613B2 (en) Interferon-alpha polypeptides and conjugates
JP2006506097A (ja) インターフェロン−αのポリペプチドおよび結合体
US7541163B2 (en) Interferon-alpha polypeptides and conjugates
JP2008545393A (ja) 進歩したインターフェロンαポリペプチド
ZA200503782B (en) Interferon-alpha polypeptides and conjugates
KR20070022279A (ko) 인터페론-알파 폴리펩티드 및 컨쥬게이트
HK1087927A (en) Interferon-alpha polypeptides and conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20071012

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20071012

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20071018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20071012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091006

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100406